Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

De novo mutations in COL4A5 identified by whole exome sequencing in 2 girls with Alport syndrome in Korea

  • Han, Kyoung Hee (Department of Pediatrics, Jeju National University School of Medicine) ;
  • Park, Jong Eun (Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine) ;
  • Ki, Chang-Seok (Green Cross Genome)
  • Received : 2018.07.11
  • Accepted : 2018.11.26
  • Published : 2019.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Alport syndrome (ATS) is an inherited glomerular disease caused by mutations in one of the type IV collagen novel chains (${\alpha}3$, ${\alpha}4$, and ${\alpha}5$). ATS is characterized by persistent microscopic hematuria that starts during infancy, eventually leading to either progressive nephritis or end-stage renal disease. There are 3 known genetic forms of ATS, namely X-linked ATS, autosomal recessive ATS, and autosomal dominant ATS. About 80% of patients with ATS have X-linked ATS, which is caused by mutations in the type IV collagen ${\alpha}5$ chain gene, COL4A5. Although an 80% mutation detection rate is observed in men with X-linked ATS, some difficulties do exist in the genetic diagnosis of ATS. Most mutations are point mutations without hotspots in the COL4A3, COL4A4, and COL4A5 genes. Further, there are insufficient data on the detection of COL4A3 and COL4A4 mutations for their comparison between patients with autosomal recessive or dominant ATS. Therefore, diagnosis of ATS in female patients with no apparent family history can be challenging. Therefore, in this study, we used whole-exome sequencing (WES) to identify mutations in type IV collagen in 2 girls with glomerular basement membrane structural changes suspected to be associated with ATS; these patients had no relevant family history. Our results revealed de novo c.4688G>A (p.Arg1563Gln) and c.2714G>A (p.Gly905Asp) mutations in COL4A5. Therefore, we suggest that WES is an effective approach to obtain genetic information in ATS, particularly in female patients without a relevant family history, to detect unexpected DNA variations.

Keywords

References

  1. Kashtan CE, Gubler MC. Inherited glomerular diseases: type IV collagen disorders. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, editors. Pediatric nephrology. 6th ed. Springer, 2009. p.621-8.
  2. Weber S, Strasser K, Rath S, Kittke A, Beicht S, Alberer M, et al. Identification of 47 novel mutations in patients with Alport syndrome and thin basement membrane nephropathy. Pediatr Nephrol 2016;31:941-55. https://doi.org/10.1007/s00467-015-3302-4
  3. Meleg-Smith S, Magliato S, Cheles M, Garola RE, Kashtan CE. Xlinked Alport syndrome in females. Hum Pathol 1998;29:404-8. https://doi.org/10.1016/S0046-8177(98)90123-X
  4. Cheong HI, Park HW, Ha IS, Choi Y. Mutational analysis of COL4A5 gene in Korean Alport syndrome. Pediatr Nephrol 2000;14:117-21. https://doi.org/10.1007/s004670050025
  5. Behjati S, Tarpey PS. What is next generation sequencing? Arch Dis Child Educ Pract Ed 2013;98:236-8. https://doi.org/10.1136/archdischild-2013-304340
  6. Artuso R, Fallerini C, Dosa L, Scionti F, Clementi M, Garosi G, et al. Advances in Alport syndrome diagnosis using next-generation sequencing. Eur J Hum Genet 2012;20:50-7. https://doi.org/10.1038/ejhg.2011.164
  7. Beicht S, Strobl-Wildemann G, Rath S, Wachter O, Alberer M, Kaminsky E, et al. Next generation sequencing as a useful tool in the diagnostics of mosaicism in Alport syndrome. Gene 2013;526:474-7. https://doi.org/10.1016/j.gene.2013.05.045
  8. Chiereghin C, Robusto M, Mastrangelo A, Castorina P, Montini G, Giani M, et al. Alport syndrome cold cases: Missing mutations identified by exome sequencing and functional analysis. PLoS One 2017;12:e0178630. https://doi.org/10.1371/journal.pone.0178630
  9. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-24. https://doi.org/10.1038/gim.2015.30
  10. Zhou J, Gregory MC, Hertz JM, Barker DF, Atkin C, Spencer ES, et al. Mutations in the codon for a conserved arginine-1563 in the COL4A5 collagen gene in Alport syndrome. Kidney Int 1993;43:722-9. https://doi.org/10.1038/ki.1993.103
  11. Wang F, Zhao D, Ding J, Zhang H, Zhang Y, Yu L, et al. Skin biopsy is a practical approach for the clinical diagnosis and molecular genetic analysis of X-linked Alport's syndrome. J Mol Diagn 2012;14:586-93. https://doi.org/10.1016/j.jmoldx.2012.06.005
  12. Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 2004;15:2514-27. https://doi.org/10.1097/01.ASN.0000141462.00630.76
  13. Wang YF, Ding J, Wang F, Bu DF. Effect of glycine substitutions on alpha5(IV) chain structure and structure-phenotype correlations in Alport syndrome. Biochem Biophys Res Commun 2004;316:1143-9. https://doi.org/10.1016/j.bbrc.2004.02.168
  14. Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant 2002;17:1218-27. https://doi.org/10.1093/ndt/17.7.1218
  15. Savige J, Sheth S, Leys A, Nicholson A, Mack HG, Colville D. Ocular features in Alport syndrome: pathogenesis and clinical significance. Clin J Am Soc Nephrol 2015;10:703-9. https://doi.org/10.2215/CJN.10581014

Cited by

  1. Identification of four novel mutations in the COL4A5 gene identified in Chinese patients with X-linked Alport syndrome vol.13, pp.2, 2019, https://doi.org/10.3892/br.2020.1311
  2. Alport syndrome combined with lupus nephritis in a Chinese family: A case report vol.9, pp.18, 2019, https://doi.org/10.12998/wjcc.v9.i18.4721
  3. Last Nucleotide Substitutions of COL4A5 Exons Cause Aberrant Splicing vol.7, pp.1, 2019, https://doi.org/10.1016/j.ekir.2021.10.012